Gilead's HIV drug shows potential in two mid-stage studies
September 24, 2014 at 10:20 AM EDT
Sept 24 (Reuters) - Gilead Sciences Inc said its HIV tablet containing tenofovir alafenamide was found better than its approved drug, Stribild, in two mid-stage studies.
